Information Provided By:
Fly News Breaks for April 26, 2017
IONS, ALNY
Apr 26, 2017 | 15:12 EDT
Piper Jaffray analyst Joshua Schimmer, while acknowledging "notable" differences between the approaches and trials of Alnylam (ALNY) and Ionis (IONS), said the fact that Alnylam's patisiran removed deposited amyloid from the thigh and leg of patients treated in a Phase 2 trial is encouraging. The analyst, who would expect Ionis' IONS-TTRRx to similarly reduce amyloid over time, is "cautiously optimistic" ahead of the company's forthcoming Phase 3 trial data and keeps an Overweight rating and $66 price target on Ionis shares.
News For ALNY;IONS From the Last 2 Days
IONS
Mar 28, 2024 | 10:40 EDT
Meetings to be held in Los Angeles on April 2 and in San Francisco on April 3 hosted by Piper Sandler.